MHRA-101357-PIP01-24-M01 (update)

Key Facts

Active Substance
Active Substance:
  • inebilizumab
Invented Name
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Xinyue
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
PIP Number MHRA-101357-PIP01-24-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for infusion
Therapeutic area
Therapeutic area:
  • Immunology -Rheumatology-Transplantation
Conditions / Indications
Conditions / Indications:
  • Treatment of immunoglobulin G4-related disease (IgG4-RD)
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance Check Procedure Number
Compliance procedure number
MHRA-101357-PIP01-24-M01-C1

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):INEBILIZUMAB.pdf
Published Date 24/10/2025